Genenta science s.p.a.GNTA.US Overview

US StockHealthcare

(No presentation for GNTA)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

GNTA Overall Performance

GNTA AI Analysis & Strategy

GNTA Recent Performance

-4.69%

Genenta science s.p.a.

0.81%

Avg of Sector

-1.14%

S&P500

GNTA PowerScanner

GNTA Key Information

GNTA Valuation Metrics

GNTA Earnings Table

GNTA Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.